Zoetis™ Files IPO Registration Statement

  Zoetis™ Files IPO Registration Statement

                       Animal Health Business Of Pfizer

Business Wire

NEW YORK -- August 13, 2012

Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc.
(zō-EH-tis), filed a registration statement with the U.S. Securities and
Exchange Commission for a potential initial public offering (IPO) of Class A
common stock. The offering is expected to represent an ownership stake of up
to 20 percent. Prior to completion of the offering, which is targeted for the
first half of 2013, Pfizer will transfer its animal health business to Zoetis.
The number of shares to be offered and the price range for the offering have
not yet been determined.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

J.P. Morgan, BofA Merrill Lynch and Morgan Stanley will act as the joint
book-running managers for the proposed IPO. When available, copies of the
preliminary prospectus relating to the proposed IPO may be obtained from J.P.
Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or telephone: 1-866-803-9204; BofA Merrill Lynch, 222
Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or
email: dg.prospectus_requests@baml.com; or Morgan Stanley, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or
telephone: 1-866-718-1649, or email: prospectus@morganstanley.com.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, as well
as nutritional products and many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as the world’s
leading biopharmaceutical company, we also collaborate with health care
providers, governments and local communities to support and expand access to
reliable, affordable health care around the world. Formore than 150
years,Pfizer has worked to makea difference for all who rely on us.

About Pfizer Animal Health

Pfizer Animal Health, a business unit of Pfizer Inc., is a global leader in
the discovery, development, manufacture and commercialization of animal health
medicines and vaccines, with a focus on both livestock and companion animals.
For more than 60 years, we have been committed to enhancing the health of
animals and bringing solutions to our customers who raise and care for them.

DISCLOSURE NOTICE: The information contained in this release is as of August
13, 2012. Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future events or
developments.

This release contains forward-looking information that involves substantial
risks and uncertainties about a potential initial public offering of a
minority ownership stake in Pfizer’s Animal Health business. Such risks and
uncertainties include, among other things, the possibility that the initial
public offering will not be consummated within the anticipated time period or
at all, including as the result of regulatory, market or other factors; risks
relating to Pfizer Animal Health as a standalone business as the result of the
variables and uncertainties inherent in business, financial and operating
performance, including, among other things, competitive developments and
general economic, political, business, industry, regulatory and market
conditions; and the potential for disruption to Pfizer’s Animal Health
business as the result of the initial public offering.

A further description of risks and uncertainties can be found in Pfizer’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in
its reports on Form 10-Q and Form 8-K.

All content set forth in this communication is subject to consultation with
works councils, unions and employee representatives as required by and subject
to local laws and regulations.

Contact:

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
joan.campion@pfizer.com
or
Investor Contact:
Chuck Triano, 212-733-3901
charles.e.triano@pfizer.com
 
Press spacebar to pause and continue. Press esc to stop.